<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2013071514001N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2013-08-09</date_registration>
      <primary_sponsor>Research and Thecnology Deputy, Golestan University of Medical Sciences</primary_sponsor>
      <public_title>comparison diazepam and clobazam in prevention recurrence of febrile seizure</public_title>
      <acronym></acronym>
      <scientific_title>A comparative study of diazepam and clobazam in prevention recurrence of febrile seizure in children with age range of 6 month to 6 years of old admitted to Gorgan Taleghani hospital in  2011-2012</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2011-11-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>280</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/13701</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>2-3</phase>
      <hc_freetext>febrile seizure.</hc_freetext>
      <i_freetext>Intervention 1: Treatment by diazepam&#13;
Chemical composition: 7-chloro-1,3-dihydro-1-methyl-5-phenyl-1-benzodiazepin-, C16H13ClN2O , molecular weight: 284.7 &#13;
Dosage: 0.33 mg/kg&#13;
Frequency of drug use: 3 times per day&#13;
Duration of drug use: 48 hours. Intervention 2: Treatment by clobazam&#13;
Chemical composition: Chloro-1-methyl-5-phenyl-1,5-benzodiazepine, C16H13ClN2O2  , molecular weight: 300.74 &#13;
Dosage: &#13;
2.5 mg for Children weighing less than 5 kg&#13;
5 mg for Children weighing 6-10 kg&#13;
7.5 mg for Children weighing 11- 15 kg&#13;
10 mg for Children weighing more than 15 kg&#13;
Frequency of drug use: 2 times per day, every 12 hours&#13;
Duration of drug use: 48 hours.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahdi Jalili Akbarian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Taleghani Hospital, Janbazan Boulevard</address>
        <city>Gorgan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 17 1222 7721</telephone>
        <email>drmja2007@yahoo.com</email>
        <affiliation>Golestan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sepodeh Amouian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Taleghani Hospital, Janbazan Boulevard</address>
        <city>Gorgan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 17 1222 7721</telephone>
        <email>amoian_sep@yahoo.com</email>
        <affiliation>Golestan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria includes patients with simple febrile seizure that their parents worry about recurrence of febrile seizure or live away medical centers and have no access to medical facilities and also children that have multiple caregiver. Exclusion criteria includes: 1) patients that have no generalized seizure or have focal signs and seizure takes more than 15 minutes and occurs more than one time in 24 hours, neurological abnormalities and abnormal neurologic examination and developmental disorders; 2) progressive neurological disease; 3) seizures during infection of the central nervous; 4) diagnosis is not febrile seizure and there are other causes and 5) abnormal EEG.</inclusion_criteria>
      <agemin>6 years</agemin>
      <agemax>72 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R56.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Febrile convulsions</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Treatment by diazepam&#13;
Chemical composition: 7-chloro-1,3-dihydro-1-methyl-5-phenyl-1-benzodiazepin-, C16H13ClN2O , molecular weight: 284.7 &#13;
Dosage: 0.33 mg/kg&#13;
Frequency of drug use: 3 times per day&#13;
Duration of drug use: 48 hours</i_keyword>
      <i_keyword>Treatment by clobazam&#13;
Chemical composition: Chloro-1-methyl-5-phenyl-1,5-benzodiazepine, C16H13ClN2O2  , molecular weight: 300.74 &#13;
Dosage: &#13;
2.5 mg for Children weighing less than 5 kg&#13;
5 mg for Children weighing 6-10 kg&#13;
7.5 mg for Children weighing 11- 15 kg&#13;
10 mg for Children weighing more than 15 kg&#13;
Frequency of drug use: 2 times per day, every 12 hours&#13;
Duration of drug use: 48 hours</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Recurrence of seizure. Timepoint: Every 3 months iduring intervention. Method of measurement: mg/kg.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Drug side effects. Timepoint: Every 3 monthes during intervention. Method of measurement: By asking parents.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Research and Thecnology Deputy, Golestan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2011-11-06</approval_date>
        <contact_name>Research and Thecnology Deputy, Golestan University of Medical Sciences</contact_name>
        <contact_address>Falsafi Higher Education Bilding, beginning of Shastkola roade, Gorgan  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
